United Kingdom Transient Ischaemic Attack Aspirin Trial "UK-TIA"

Completed

Phase N/A Results

Trial Description

To compare the relative efficacies of two different doses of aspirin taken daily on a long-term basis in the secondary prevention of stroke.

Interventions

Trial Design

Randomized, double-blind, placebo-controlled trial of 2435 patients at 33 centers.

Patient Involvement

Patients were randomized to receive either aspirin two 300 mg tablets twice daily, aspirin two 150 mg tablets once daily and placebo once daily, or placebo twice daily. If patients complained of indigestion they were advised to omit the second daily dose of tablets. If they still complained of indigestion, they were told to take just one tablet of the first daily dose. If indigestion persisted, they were advised to transfer to enteric coated trial medication and if necessary reduce dose to one tablet daily. Patients were seen every 4 months until the scheduled end of the trial or prior death or emigration. If they were not able or willing to go the neurological clinics for follow-up, their general practitioners were contacted for information. Treatment was continued for an average of four years range .

Outcomes

Type Measure Time Frame Safety Issue
Primary Time to composite event of major stroke (modified Rankin scale score >=3), myocardial infarction or vascular death.
Secondary Adverse effects.

Sponsors

Medical Research Council, Beecham Products, Eli Lilly, Evans Medical/Glaxo, Wasell Packaging, Aspirin Foundation